Russell Investments Group Ltd. Has $15.53 Million Position in Bio-Techne Corp (NASDAQ:TECH)
Russell Investments Group Ltd. raised its stake in shares of Bio-Techne Corp (NASDAQ:TECH) by 3.7% during the second quarter, Holdings Channel reports. The fund owned 132,191 shares of the biotechnology company’s stock after buying an additional 4,679 shares during the period. Russell Investments Group Ltd.’s holdings in Bio-Techne Corp were worth $15,532,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Quantitative Systematic Strategies LLC acquired a new stake in Bio-Techne Corp during the second quarter valued at about $271,000. Huntington National Bank raised its position in Bio-Techne Corp by 6.0% in the second quarter. Huntington National Bank now owns 2,138 shares of the biotechnology company’s stock worth $251,000 after buying an additional 121 shares in the last quarter. Conestoga Capital Advisors LLC raised its position in Bio-Techne Corp by 6.5% in the second quarter. Conestoga Capital Advisors LLC now owns 272,828 shares of the biotechnology company’s stock worth $32,057,000 after buying an additional 16,615 shares in the last quarter. State Treasurer State of Michigan raised its position in Bio-Techne Corp by 1.3% in the second quarter. State Treasurer State of Michigan now owns 15,400 shares of the biotechnology company’s stock worth $1,810,000 after buying an additional 200 shares in the last quarter. Finally, First National Bank of Omaha raised its position in Bio-Techne Corp by 6.5% in the second quarter. First National Bank of Omaha now owns 29,130 shares of the biotechnology company’s stock worth $2,714,000 after buying an additional 1,770 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.
Shares of Bio-Techne Corp (NASDAQ TECH) traded up 0.939% on Thursday, hitting $115.515. 95,424 shares of the stock were exchanged. Bio-Techne Corp has a one year low of $95.68 and a one year high of $121.94. The firm has a market capitalization of $4.31 billion, a PE ratio of 56.075 and a beta of 0.79. The company has a 50-day moving average price of $116.51 and a 200-day moving average price of $108.70.
Bio-Techne Corp (NASDAQ:TECH) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.10. Bio-Techne Corp had a net margin of 12.93% and a return on equity of 14.18%. The company had revenue of $156.60 million during the quarter, compared to the consensus estimate of $150.25 million. During the same quarter last year, the firm posted $0.92 EPS. The company’s quarterly revenue was up 16.2% on a year-over-year basis. Equities research analysts expect that Bio-Techne Corp will post $3.97 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 18th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date of this dividend is Wednesday, August 16th. Bio-Techne Corp’s dividend payout ratio (DPR) is presently 65.98%.
COPYRIGHT VIOLATION WARNING: “Russell Investments Group Ltd. Has $15.53 Million Position in Bio-Techne Corp (NASDAQ:TECH)” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/10/russell-investments-group-ltd-has-15-53-million-position-in-bio-techne-corp-nasdaqtech.html.
A number of research analysts have weighed in on the stock. Deutsche Bank AG boosted their target price on shares of Bio-Techne Corp from $130.00 to $132.00 and gave the stock a “buy” rating in a research report on Wednesday. Zacks Investment Research raised shares of Bio-Techne Corp from a “sell” rating to a “hold” rating in a research report on Saturday, May 6th. BidaskClub lowered shares of Bio-Techne Corp from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Citigroup Inc. reissued a “buy” rating and set a $125.00 target price (up previously from $115.00) on shares of Bio-Techne Corp in a research report on Wednesday, May 3rd. Finally, Wells Fargo & Company assumed coverage on shares of Bio-Techne Corp in a research report on Thursday, July 13th. They set a “market perform” rating for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Bio-Techne Corp presently has a consensus rating of “Buy” and a consensus price target of $125.20.
In other news, Director Charles A. Dinarello sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, May 31st. The shares were sold at an average price of $111.37, for a total transaction of $556,850.00. Following the completion of the sale, the director now owns 12,473 shares in the company, valued at approximately $1,389,118.01. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last three months, insiders sold 10,200 shares of company stock valued at $1,135,648. Insiders own 2.70% of the company’s stock.
Bio-Techne Corp Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH).
Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.